News

Biosenta Inc. announced that Gary LeRoux, past President and CEO of the Canadian Coatings Association (CCA), has joined the company’s advisory board. Mr. LeRoux brings more than 30 years of leadership experience. “Gary’s unmatched experience in coatings, regulatory policy, and industry partnerships is a tremendous asset as we advance the commercialization of Tri-­Filler®,” said Am Gill, President and CEO of Biosenta. “His perspective will help us accelerate adoption across ke

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

A University of Calgary research team, partnered with Biosenta Inc., has developed a method to transform limestone into a long-lasting antimicrobial nanoparticle. This new "shell and core" technology has a durable active ingredient, calcium hydroxide, and has been proven effective against various harmful pathogens. Potential applications include enhancing concrete, paint for healthcare settings, and coatings for food packaging and high-touch surfaces.

Kris Hans shares how Biosenta is tackling the antimicrobial health crisis at the source, and why this work matters now more than ever.

Biosenta Inc. announces licensing agreement

Biosenta granted to Lightweight Concrete Solutions a license to use Biosenta’s Tri-Filler® technology and get fee of C$200,000 and royalties

UoC professor taking about a solution fighting a drug-resistant fungus that has become a big issue for hospitals in the U.S. and Canada.

Biosenta Inc. announces further advances in research and development of the Tri-Filler™ particle.

Biosenta announces entering into of agreement to terminate joint venture

Biosenta Inc. announces that it has ceased negotiations with Voran Group Ventures Ltd.

Chelsey Reschke is one of 47 Canadians attending the G20 Young Entrepreneurs’ Alliance summit in Hamburg from Oct. 27 to 28.

Biosenta Inc. has signed an MOU with Voran Group Ventures Ltd. for the commercialization of Biosenta’s Tri-Filler® antimicrobial products.

University of Calgary very encouraging anti-bacterial Biosenta particles for construction industry

Biosenta Inc. announces that it has entered into an agreement to settle $1,015,088.47 of debt through issuance of 3,625,315 common shares.